Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q4 EPS of ($1.28), $0.58 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $9.6 million versus the consensus estimate of $10.82 million.

The Company had approximately $181.6 million in cash and cash equivalents as of December 31, 2021.

For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.